Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/22653
Başlık: Risk factors and complications of intracranial pressure monitoring with a fiberoptic device
Yazarlar: Uludağ Üniversitesi/Tıp Fakültesi/Nöroşirürji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Anestezi ve Reanimasyon Anabilim Dalı.
0000-0003-3633-7919
Bekar, Ahmet
Doğan, Şeref
Abaş, Faruk
Caner, Burcu
Korfalı, Gülşen
Kocaeli, Hasan
Yılmazlar, Selçuk
Korfalı, Ender
Caner, Burcu
AAI-6531-2021
AAH-5070-2021
7102693077
6603677218
8546184300
25027089000
6701462594
6603500567
6603059483
7004641343
Anahtar kelimeler: Complications
Fiberoptic device
Intracranial pressure
Monitoring
Brain-tissue pressure
Head-injured patients
Clinical-evaluation
Infectious complications
Aggressive treatment
Experience
Duration
Neurosciences & neurology
Yayın Tarihi: Şub-2009
Yayıncı: Elsevier
Atıf: Bekar, A. vd. (2009). "Risk factors and complications of intracranial pressure monitoring with a fiberoptic device". Journal of Clinical Neuroscience, 16(2), 236-240.
Özet: We prospectively investigated the complications associated with intraparenchymal intracranial pressure (ICP) monitoring using the Camino intracranial pressure device. A fiberoptic ICP monitoring transducer was implanted in 631 patients. About half of the patients (n = 303) also received an external ventricular drainage set (EVDS). The durations (mean +/- SD) of ICP monitoring in patients without and with an EVDS were 6.5 +/- 4.4 and 7.3 +/- 5.1 days, respectively. Infection occurred in 6 patients with only an ICP transducer (6/328, 1.8%) and 24 patients with an EVDS also (24/303, 7.9%). The duration of monitoring had no effect on infection, whereas the use of an EVDS for more than 9 days increased infection risk by 5.11 times. Other complications included transducer disconnection (2.37%), epidural hematoma (0.47%), contusion (0.47%), defective probe (0.31%), broken transducer (0.31%), dislocation of the fixation screw (0.15%), and intraparenchymal hematoma (0.15%). In conclusion, intraparenchymal ICP monitoring systems can be safely used in patients who either have, or are at risk of developing, increased ICP.
URI: https://doi.org/10.1016/j.jocn.2008.02.008
https://www.sciencedirect.com/science/article/pii/S0967586808001082
http://hdl.handle.net/11452/22653
ISSN: 0967-5868
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.